市場調査レポート
商品コード
1344584

コンパニオン診断市場 - 診断薬の未来 - 用途別、技術別、資金調達別 - エグゼクティブコンサルタントガイド付き(2023年~2027年)

Companion Diagnostic Markets, The Future of Diagnostics By Application, Technology and Funding. With Executive and Consultant Guides 2023-2027

出版日: | 発行: Howe Sound Research | ページ情報: 英文 546 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
コンパニオン診断市場 - 診断薬の未来 - 用途別、技術別、資金調達別 - エグゼクティブコンサルタントガイド付き(2023年~2027年)
出版日: 2023年09月01日
発行: Howe Sound Research
ページ情報: 英文 546 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

コンパニオン診断は、診断業界に革命を起こそうとしています。市場はラボからクリニックへと移行しつつあります。腫瘍学、特に免疫腫瘍学がその先頭を走っています。FDAはこの未来の診断技術に門戸を開いています。

当レポートは、世界のコンパニオン診断市場について調査し、市場の概要とともに、用途別、技術別、資金調達別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

第3章 市場概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計装サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関
  • 個別化医療とコンパニオン診断
  • 染色体、遺伝子、エピジェネティクス
  • 癌遺伝子
  • 産業構造の関与

第4章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測、自動化、診断の動向

第5章 最近の開発

第6章 主要参入企業のプロファイル

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agilent/Dako
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Burning Rock
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • CellCarta
  • CellMax Life
  • Cepheid(Danaher)
  • Charles River Laboratories
  • Circulogene
  • Cizzle Biotech
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Dxcover
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Fabric Genomics
  • Fluxion Biosciences
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fyr Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • INOVIQ
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • PamGene
  • Panagene
  • Perkin Elmer(Revvity)
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • Precision Medicine Group
  • PrecisionMed
  • Predicine
  • Promega
  • Qiagen
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sema4 Holdings
  • Sense Biodetection
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Todos Medical
  • Ultima Genomics
  • Veracyte
  • Volition
  • Vortex Biosciences
  • Vyant Bio

第7章 世界のコンパニオン診断市場

  • 世界市場概要、国別
  • 世界市場- 概要、用途別
  • 世界市場- 概要、資金調達別
  • 世界市場の概要、技術別

第8章 世界のコンパニオン診断市場- 用途別

  • 腫瘍科
  • 神経内科
  • 心臓病科
  • その他

第9章 世界のコンパニオン診断市場- 資金調達別

  • 医薬品
  • ベンチャー
  • 臨床
  • その他

第10章 世界のコンパニオン診断市場- 技術別

  • 次世代シーケンシング
  • PCR
  • IHC/ISH
  • その他

第11章 付録

図表

Table of Tables

  • Table 1: FDA Approved Companion Dx
  • Table 2: Market Players by Type
  • Table 3: The Base Pairs
  • Table 4: Five Factors Driving Growth
  • Table 5: Four Factors Limiting Growth
  • Table 6: Seven Key Diagnostic Laboratory Technology Trends
  • Table 7: Global Companion Diagnostic Market by Region
  • Table 8: Global Market by Application
  • Table 9: Global Market by Funding Source
  • Table 10: Global Market by Technology
  • Table 11: Oncology by Country
  • Table 12: Neurology by Country
  • Table 13: Cardiology by Country
  • Table 14: Other Application by Country
  • Table 15: Pharmaceutical by Country
  • Table 16: Venture by Country
  • Table 17: Clinical by Country
  • Table 18: Other Funding by Country
  • Table 19: Next Generation Sequencing by Country
  • Table 20: PCR by Country
  • Table 21: IHC/ISH by Country
  • Table 22: Other Technology by Country
  • Table 23: Clinical Laboratory Fee Schedule
  • Table 24: The Most Common Assays
  • Table 25: Largest Revenue Assays
  • Table 26: Pharmacogenomic Biomarkers

Table of Figures

  • Figure 1: Global Healthcare Spending
  • Figure 2: The Lab Test Pie-Wholesale & Retail
  • Figure 3: The Road to Diagnostics
  • Figure 4: DNA Strands and Chromosomes
  • Figure 5: Karyogram of Human Chromosomes
  • Figure 6: Size of Various Genomes
  • Figure 7: Germline vs Somatic Mutations
  • Figure 8: Comparing Genomic Diagnostic and Traditional Testing
  • Figure 9: The Changing Age of The World's Population
  • Figure 10: Health Care Consumption by Age
  • Figure 11: Cancer Incidence by Age
  • Figure 12: Centralized vs. Decentralized Laboratory Service
  • Figure 13: A Highly Multiplexed Syndromic Testing Unit
  • Figure 14: The Real Cost to Sequence the Human Genome
  • Figure 15: The Codevelopment Process
  • Figure 16: Comparing MDx Diagnostic and Traditional Testing
  • Figure 17: Base Year Country Market Share Chart
  • Figure 18: CDx Market by Application-Base vs. Final Year
  • Figure 19: CDx Market by Application Base Year
  • Figure 20: CDx Market by Application Final Year
  • Figure 21: Application Type Share by Year
  • Figure 22: Funding Source - Base vs. Final Year
  • Figure 23: Funding Source Market Base Year
  • Figure 24: Funding Source Market Final Year
  • Figure 25: Funding Source Share by Year
  • Figure 26: Technology - Base vs. Final Year
  • Figure 27: Technology Market Base Year
  • Figure 28: Technology Market Final Year
  • Figure 29: Technology Share by Year
  • Figure 30: Oncology Growth
  • Figure 31: Neurology Growth
  • Figure 32: Cardiology Growth
  • Figure 33: Other Application Growth
  • Figure 34: Pharmaceutical Growth
  • Figure 35: Venture Growth
  • Figure 36: Clinical Growth
  • Figure 37: Other Funding Growth
  • Figure 38: Next Generation Sequencing Growth
  • Figure 39: PCR Growth
  • Figure 40: IHC/ISH Growth
  • Figure 41: Other Technology Growth
目次

OVERVIEW:

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country or specific area in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Companion Diagnostics?
  • 2.2. The Personalized Medicine Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size.
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare and the IVD Industry
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Diagnostics
    • 2.5.3. Important Role of Insurance for Diagnostics

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Personalized Medicine and Companion Diagnostics
    • 3.2.1. Basics
    • 3.2.2. Method
    • 3.2.3. Disease risk assessment
    • 3.2.4. Applications
    • 3.2.5. Diagnosis and intervention
      • 3.2.5.1. Companion Diagnostics
    • 3.2.6. Drug development and usage
    • 3.2.7. Respiratory proteomics
    • 3.2.8. Cancer genomics
    • 3.2.9. Population screening
    • 3.2.10. Challenges
    • 3.2.11. Regulatory oversight
    • 3.2.12. Intellectual property rights
    • 3.2.13. Reimbursement policies
    • 3.2.14. Patient privacy and confidentiality
  • 3.3. Chromosomes, Genes and Epigenetics
    • 3.3.1. Chromosomes
    • 3.3.2. Genes
    • 3.3.3. Epigenetics
  • 3.4. Cancer Genes
    • 3.4.1. Germline vs Somatic
    • 3.4.2. Changing Clinical Role
  • 3.5. Structure of Industry Plays a Part
    • 3.5.1. New Pharmaceutical Funding Market
    • 3.5.2. Economies of Scale
      • 3.5.2.1. Hospital vs. Central Lab
    • 3.5.3. Physician Office Labs
    • 3.5.4. Physicians and POCT

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Level of Care.
    • 4.1.2. Immuno-oncology.
    • 4.1.3. Liability.
    • 4.1.4. The Aging World
  • 4.2. Factors Limiting Growth
    • 4.2.1. State of knowledge.
    • 4.2.2. Genetic Blizzard.
    • 4.2.3. Protocol Resistance.
    • 4.2.4. Regulation and coverage.
  • 4.3. Instrumentation, Automation and Diagnostic Trends
    • 4.3.1. Traditional Automation and Centralization
    • 4.3.2. The New Automation, Decentralization and Point Of Care
    • 4.3.3. Instruments Key to Market Share
    • 4.3.4. Bioinformatics Plays a Role
    • 4.3.5. PCR Takes Command
    • 4.3.6. Next Generation Sequencing Fuels a Revolution
    • 4.3.7. NGS Impact on Pricing
    • 4.3.8. Whole Genome Sequencing, A Brave New World
    • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
    • 4.3.10. Shifting Role of Diagnostics

5. Companion Diagnostics Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Agilent CDx Assay IVDR Certified
  • 5.3. ARUP Laboratories Gets Approval for Gene Therapy CDx
  • 5.4. Guardant Health Gets Medicare Coverage for Liquid Biopsy Test
  • 5.5. Amoy Dx PLC Panel Gets Approval in Japan as CDx
  • 5.6. UnitedHealthcare Expands Precision Oncology Dx Coverage
  • 5.7. JaxBio to Create Array-Based Cancer Tests
  • 5.8. Agilent, Qiagen Win FDA Approvals Companion Diagnostics
  • 5.9. Navignostics Using Single-Cell Spatial Proteomics
  • 5.10. HMNC Brain Health to Develop Companion Diagnostics
  • 5.11. Propath UK, Nucleai Partner on Spatial Proteomics
  • 5.12. Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based Companion Diagnostics
  • 5.13. Almac, AstraZeneca Strike CDx Development Pact
  • 5.14. Avalon GloboCare, Lu Daopei Hematology Institute to Develop Cell Therapy CDx
  • 5.15. Burning Rock Secures Lung Cancer NGS Test Approval in China
  • 5.16. TenSixteen Bio Developing Drugs, Companion NGS Tests
  • 5.17. Guardant Health Plans New Comprehensive Assay
  • 5.18. Thermo Fisher, Oncocyte Ink Comarketing Deal for Cancer IVDs
  • 5.19. Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test
  • 5.20. Japanese Approves Thermo Fisher Scientific Oncomine Assay as CDx
  • 5.21. Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug
  • 5.22. Natera Aims to Lead Market in Solid Tumor Adjuvant CDx
  • 5.23. Oncocyte Details Expansions Plans
  • 5.24. Agilent Acquires Resolution Biosciences
  • 5.25. Qiagen, Inovio Expand CDx Partnership
  • 5.26. AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
  • 5.27. NeoGenomics to Grow Through CDx Agreements, Acquisitions
  • 5.28. Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
  • 5.29. Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
  • 5.30. FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
  • 5.31. Promega to Develop MSI Assay as CDx
  • 5.32. Guardant Health to Develop CDx for Janssen
  • 5.33. Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
  • 5.34. FDA Approval for FoundationOne®CDx
  • 5.35. FDA finalizes CDx Guidance
  • 5.36. QIAGEN Launches CDx Therascreen BRAF Test

6. Profiles of Key Players

  • 6.1. 10x Genomics, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. AccuraGen Inc.
  • 6.4. Adaptive Biotechnologies
  • 6.5. Aethlon Medical
  • 6.6. Agilent/Dako
  • 6.7. Anchor Dx
  • 6.8. ANGLE plc
  • 6.9. ARUP Laboratories
  • 6.10. AVIVA Systems Biology
  • 6.11. Baylor Miraca Genetics Laboratories
  • 6.12. Beckman Coulter Diagnostics
  • 6.13. Becton, Dickinson and Company
  • 6.14. BGI Genomics Co. Ltd
  • 6.15. Bioarray Genetics
  • 6.16. Biocartis
  • 6.17. Biocept, Inc.
  • 6.18. Biodesix Inc.
  • 6.19. BioFluidica
  • 6.20. BioGenex
  • 6.21. BioIVT
  • 6.22. Biolidics Ltd
  • 6.23. bioMérieux Diagnostics
  • 6.24. Bioneer Corporation
  • 6.25. Bio-Rad Laboratories, Inc
  • 6.26. Bio-Reference Laboratories
  • 6.27. Bio-Techne
  • 6.28. Bioview
  • 6.29. Bolidics
  • 6.30. Boreal Genomics
  • 6.31. Bristol-Myers Squibb
  • 6.32. Burning Rock
  • 6.33. Cardiff Oncology
  • 6.34. Caris Molecular Diagnostics
  • 6.35. Castle Biosciences, Inc.
  • 6.36. CellCarta
  • 6.37. CellMax Life
  • 6.38. Cepheid (Danaher)
  • 6.39. Charles River Laboratories
  • 6.40. Circulogene
  • 6.41. Cizzle Biotech
  • 6.42. Clinical Genomics
  • 6.43. Cytolumina Technologies Corp.
  • 6.44. Datar Cancer Genetics Limited
  • 6.45. Diagnologix LLC
  • 6.46. Diasorin S.p.A.
  • 6.47. Dxcover
  • 6.48. Element Biosciences
  • 6.49. Enzo Biochem
  • 6.50. Epic Sciences
  • 6.51. Epigenomics AG
  • 6.52. Eurofins Scientific
  • 6.53. Fabric Genomics
  • 6.54. Fluxion Biosciences
  • 6.55. Freenome
  • 6.56. FUJIFILM Wako Diagnostics
  • 6.57. Fyr Diagnostics
  • 6.58. GeneFirst Ltd.
  • 6.59. Genetron Holdings
  • 6.60. GenomOncology
  • 6.61. GILUPI Nanomedizin
  • 6.62. Guardant Health
  • 6.63. HansaBiomed
  • 6.64. HeiScreen
  • 6.65. Helomics
  • 6.66. HTG Molecular Diagnostics
  • 6.67. iCellate
  • 6.68. Illumina
  • 6.69. Incell Dx
  • 6.70. Inivata
  • 6.71. INOVIQ
  • 6.72. Integrated Diagnostics
  • 6.73. Invitae Corporation
  • 6.74. Invivogen
  • 6.75. Invivoscribe
  • 6.76. Janssen Diagnostics
  • 6.77. Lunglife AI Inc
  • 6.78. MDNA Life SCIENCES, Inc.
  • 6.79. MDx Health
  • 6.80. Menarini Silicon Biosystems
  • 6.81. Mesa Laboratories, Inc.
  • 6.82. Millipore Sigma
  • 6.83. Miltenyi Biotec
  • 6.84. miR Scientific
  • 6.85. Myriad Genetics/Myriad RBM
  • 6.86. NantHealth, Inc.
  • 6.87. Natera
  • 6.88. NeoGenomics
  • 6.89. NGeneBio
  • 6.90. Novogene Bioinformatics Technology Co., Ltd.
  • 6.91. Oncocyte
  • 6.92. OncoDNA
  • 6.93. Ortho Clinical Diagnostics
  • 6.94. Oxford Nanopore Technologies
  • 6.95. PamGene
  • 6.96. Panagene
  • 6.97. Perkin Elmer (Revvity)
  • 6.98. Personal Genome Diagnostics
  • 6.99. Personalis
  • 6.100. Precipio
  • 6.101. Precision Medicine Group
  • 6.102. PrecisionMed
  • 6.103. Predicine
  • 6.104. Promega
  • 6.105. Qiagen
  • 6.106. Rarecells SAS
  • 6.107. RareCyte
  • 6.108. Roche Molecular Diagnostics
  • 6.109. Screencell
  • 6.110. Sema4 Holdings
  • 6.111. Sense Biodetection
  • 6.112. Siemens Healthineers
  • 6.113. simfo GmbH
  • 6.114. Singlera Genomics Inc.
  • 6.115. Singular Genomics
  • 6.116. Singulomics
  • 6.117. SkylineDx
  • 6.118. Standard BioTools
  • 6.119. Stilla Technologies
  • 6.120. Sysmex Inostics
  • 6.121. Tempus Labs, Inc.
  • 6.122. Thermo Fisher Scientific Inc.
  • 6.123. Todos Medical
  • 6.124. Ultima Genomics
  • 6.125. Veracyte
  • 6.126. Volition
  • 6.127. Vortex Biosciences
  • 6.128. Vyant Bio

7. The Global Market for Companion Diagnostics

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart-Global Market by Country
  • 7.2. Global Market by Application-Overview
    • 7.2.1. Table - Global Market by Application
    • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Application - Base Year
    • 7.2.4. Chart - Global Market by Application - Final Year
    • 7.2.5. Chart - Global Market by Application - Share by Year
  • 7.3. Global Market Funding Source-Overview
    • 7.3.1. Table - Global Market by Funding Source
    • 7.3.2. Chart - Global Market Funding Source - Base/Final Year Comparison
    • 7.3.3. Chart - Global Market Funding Source - Base Year
    • 7.3.4. Chart - Global Market Funding Source - Final Year
    • 7.3.5. Chart - Global Market Funding Source - Share by Year
  • 7.4. Global Market Technology-Overview
    • 7.4.1. Table - Global Market by Technology
    • 7.4.2. Chart - Global Market Technology - Base/Final Year Comparison
    • 7.4.3. Chart - Global Market Technology - Base Year
    • 7.4.4. Chart - Global Market Technology - Final Year
    • 7.4.5. Chart - Global Market Technology - Share by Year

8. Global Companion Diagnostic Markets - By Application

  • 8.1. Oncology
    • 8.1.1. Table Oncology - by Country
    • 8.1.2. Chart-Oncology Growth
  • 8.2. Neurology
    • 8.2.1. Table Neurology - by Country
    • 8.2.2. Chart-Neurology Growth
  • 8.3. Cardiology
    • 8.3.1. Table Cardiology - by Country
    • 8.3.2. Chart-Cardiology Growth
  • 8.4. Other Application
    • 8.4.1. Table Other Application - by Country
    • 8.4.2. Chart-Other Application Growth

9. Global Companion Diagnostic Markets - Funding Source

  • 9.1. Global Market Pharmaceutical
    • 9.1.1. Table Pharmaceutical - by Country
    • 9.1.2. Chart-Pharmaceutical Growth
  • 9.2. Global Market Venture
    • 9.2.1. Table Venture - by Country
    • 9.2.2. Chart-Venture Growth
  • 9.3. Global Market Clinical
    • 9.3.1. Table Clinical - by Country
    • 9.3.2. Chart-Clinical Growth
  • 9.4. Global Market Other Funding
    • 9.4.1. Table Other Funding - by Country
    • 9.4.2. Chart-Other Funding Growth

10. Global Companion Diagnostic Markets - Technology

  • 10.1. Global Market Next Generation Sequencing
    • 10.1.1. Table Next Generation Sequencing - by Country
    • 10.1.2. Chart-Next Generation Sequencing Growth
  • 10.2. Global Market PCR
    • 10.2.1. Table PCR - by Country
    • 10.2.2. Chart-PCR Growth
  • 10.3. Global Market IHC/ISH
    • 10.3.1. Table IHC/ISH - by Country
    • 10.3.2. Chart-IHC/ISH Growth
  • 10.4. Global Market Other Technology
    • 10.4.1. Table Other Technology - by Country
    • 10.4.2. Chart-Other Technology Growth

11. Appendices

  • 11.1. United States Medicare System: Clinical Laboratory Fees Schedule
  • 11.2. The Most Used IVD Assays
  • 11.3. The Highest Grossing Assays
  • 11.4. Pharmacogenomic Biomarkers in Drug Labeling